Limited data exist evaluating outcomes in patients with serious Streptococcus anginosus group infections, particularly bacteraemia. A retrospective, single-centre cohort study was conducted to characterize potential risk factors along with clinical and microbiological outcomes in patients with S. anginosus group bacteraemia (SAGB). Adult inpatients with SAGB identified using the Verigene Gram-positive blood culture assay between March 2013 and April 2014 were included. Patients aged j18 or .89 years, those with SAGB identified at an outside facility and those who were incarcerated were excluded. Differences between groups were explored using a Wilcoxon rank-sum test, x 2 test, Student's t-test or Fisher's exact test as appropriate and a two-tailed P value of j0.05 was considered statistically significant. The 34 patients who met the inclusion criteria were 57¡14 (mean¡SD) years old and had a median Charlson co-morbidity index of 4 [interquartile range (IQR) 1-6] and 10 (29 %) were immunosuppressed at baseline. Almost half (47 %) had received antibiotics in the previous 90 days. Twelve (35 %) patients had gastrointestinal malignancies and the commonest source of bacteraemia was the gastrointestinal tract (53 %). The primary species responsible for SAGB was S. anginosus (68 %), and overall susceptibility to penicillin was 91 %. Patients were most often treated with a b-lactam/blactamase inhibitor combination (36 %) for a duration of 8 (IQR 4-13) days. Length of stay (LOS) and infection-related LOS were 10 (IQR 5-17) and 9 (IQR 4-12) days, respectively. Twenty [59 %] patients achieved a clinical cure, while 29 (85 %) achieved a microbiological cure. Four (12 %) patients died and one patient was readmitted within 30 days. In the largest cohort of patients with SAGB to date, gastrointestinal malignancies may have been an important risk factor for SAGB, while rapid identification via a microarray assay likely contributed to improved disease recognition and timely pharmacological and non-pharmacological therapy.
INTRODUCTION
The Streptococcus anginosus (or Streptococcus milleri) group (SAG) of bacteria is one of five groups collectively known as the viridans group streptococci (Whiley & Beighton, 1991) . This group consists of three distinct species, Streptococcus intermedius, Streptococcus constellatus and Streptococcus anginosus, and is well recognized as a cause of invasive pyogenic infections at almost every anatomical site, differentiating it from other viridans group streptococci (Whiley & Beighton, 1991; Whiley et al., 1992) . Like other streptococci, the SAG may produce full, partial or no haemolysis on sheep blood agar and often exhibits Lancefield antigens A, C, F or G (Brogan et al., 1997) . This diversity in both haemolysis and Lancefield groupings has made identification of this group difficult, even with molecular taxonomic techniques (Khot et al., 2012) . The SAG are considered normal flora of the human gastrointestinal IP: 54.70.40.11
On: Sat, 29 Dec 2018 20:46:26 tract and oropharynx but are often associated with abscess formation and metastatic infections when pathogenic (Bantar et al., 1996; Stelzmueller et al., 2009; Whiley et al., 1992) . Although all the viridans group streptococci have the propensity to cause severe invasive infections, SAG organisms are increasingly isolated from clinically significant specimens and are associated with significant morbidity and mortality (Belko et al., 2002; Bert et al., 1998; Ruoff, 1988) .
The routine identification and classification of groups or species within viridans group streptococci are not performed regularly due to the lack of precision of available biochemical and phenotypic identification methods and the consensus that speciation is not generally considered necessary due to the predictable penicillin susceptibility of this group (Clarridge et al., 1999; Whiley et al., 1990) . Newly introduced molecular diagnostic techniques, such as microarray technology, allow rapid and accurate identification of the SAG from positive blood cultures. The importance of delineating the SAG from other viridans group streptococci is becoming increasingly well recognized as the prevalence and pathogenicity of disseminated infections due to this group continue to escalate (Bert et al., 1998; Stelzmueller et al., 2009) .
Although previous literature has suggested that specific species within the S. anginosus group are associated with particular clinical syndromes, these associations have not been reproduced (Junckerstorff et al., 2014) . What is known is that the SAG are frequently pathogenic and cause contiguous or distant infections including pyogenic brain and liver abscesses and, rarely, bacteraemia and endocarditis (Belko et al., 2002; Bert et al., 1998; Stelzmueller et al., 2009) . Nearly all isolates are susceptible to penicillin, while resistance has been encountered to newer agents, including daptomycin (Palacio et al., 2011) . Treatment of infections due to S. anginosus almost always involves source control via surgical excision or abscess drainage along with antimicrobial therapy as appropriate (Belko et al., 2002; Bert et al., 1998; Stelzmueller et al., 2009) .
Overall, there are limited data evaluating clinical outcomes in patients with invasive SAG infections, particularly bacteraemia, and the appropriate therapeutic modalities remain largely unknown. The objective of this study was to explore potential risk factors, epidemiology, and clinical and microbiological outcomes in patients with SAG bacteraemia (SAGB) identified via microarray-based molecular technology.
METHODS
Study design. This was a retrospective, single-centre study conducted at The Ohio State University Wexner Medical Centre (OSUWMC), a 1250-bed tertiary-care academic medical centre located in Columbus, Ohio. The study was approved by the Office of Responsible Research Practices Institutional Review Board with a waiver of consent granted. Adult inpatients with at least one blood culture positive for SAG identified by the Verigene Gram-positive blood culture (BC-GP) assay (Nanosphere) between March 2013 and April 2014 were evaluated. Only the first episode of bacteraemia per patient during the study period was analysed. Exclusion criteria included those patients aged j18 or w89 years, those with SAG identified at an outside facility, and patients who were incarcerated.
Microbiology workflow. Blood cultures were incubated using the BD BACTEC 9240 system (Becton Dickinson). Aliquots from bottles that gave a positive signal were Gram stained and subcultured into appropriate medium. Prior to implementation of the BC-GP machine, the SAG was not routinely identified to the species level and was reported as a-haemolytic, viridans group streptococci, unless identification by 16S rRNA gene sequencing was specifically requested. The BC-GP was performed 24 h a day, 7 days a week by the clinical microbiology laboratory on all initially positive blood cultures that demonstrated Gram-positive organisms on the Gram stain smear. The BC-GP is an on-demand microarray test that employs solid-phase support with capture probes representing nucleic acid sequences that complement those of bacterial DNA. Within approximately 2.5 h, the BC-GP test can identify the presence of the following organisms from positive blood cultures: Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, SAG, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium and Listeria spp. along with three resistance markers (mecA, vanA and vanB). Microbiology laboratory personnel notified the patient's treating physician of the Gram stain result and BC-GP identification simultaneously from a positive blood culture. All BC-GP results were confirmed by conventional microbiological methods using the MicroScan WalkAway System (Siemens Diagnostics) and by matrixassisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker Daltonik). Final organism identification and susceptibility testing was completed with results reported in the electronic medical record without additional notification. Organism susceptibilities were tested using the MicroScan MICroSTREP plus panel with 3 % lysed horse blood (Beckman Coulter) or an Etest (bioMérieux). Prior to August 2013, only penicillin, ceftriaxone and vancomycin susceptibilities to the SAG were routinely reported for clinical use. After August 2013, susceptibilities to all of the antibiotics shown in Table 2 were reported if susceptibilities were performed on the SAG isolate. After the conclusion of this study, the reference library for the Bruker MALDI-TOF MS instrument was updated to allow individual species identification of the SAG. For the purposes of this research, the SAG isolates included in this study were removed from frozen storage, and species identification was performed using the MALDI-TOF MS system. Additionally, haemolysis was characterized for each isolate and the full panel of susceptibilities was tested via the MicroScan MICroSTREP plus panel system (CLSI, 2014) . If there was inadequate growth for susceptibility testing within the automated broth microdilution system, susceptibilities were performed using an Etest for ceftriaxone, penicillin and vancomycin.
Data and outcomes. Data were obtained from OSUWMC's electronic medical record and Information Warehouse. Data obtained included: age, gender, antibiotic exposure in the previous 90 days, receipt of immunosuppressive therapy in the previous 90 days (defined as cytotoxic agents, corticosteroids at a dosage of i15 mg of prednisone equivalence daily for w1 week within 4 weeks, anti-rejection medications within 2 weeks, absolute neutrophil count v500 cells mm 23 or CD4 count v200 cells mm 23 ), Charlson co-morbidity index (Charlson et al., 1994) , Pitt Bacteraemia Score (Rhee et al., 2009) , intensive care unit (ICU) admission, ICU length of stay (LOS), source of SAGB, source removal, time to source removal, SAG antibiotic susceptibilities, empirical therapy, definitive therapy, infectious diseases (ID) consult and time to ID consult. Bacteraemia was defined according to the Centers for Disease Control and Prevention definition (Garner et al., 1988) .
Clinical outcomes included clinical cure, duration of bacteraemia, time to effective therapy, duration of therapy, hospital LOS, infectionrelated LOS, 30-day all-cause mortality, infection-related mortality and 30-day re-admission for bacteraemia. Clinical cure was defined as the resolution of baseline signs and symptoms, a white blood cell count v10 000 cells mm 23 , absence of oral temperature w38 uC for 24 consecutive hours and a documented negative blood culture. Clinical cure was reviewed independently by an ID physician (V.C., P.S., M.A. or B.S.M). Duration of bacteraemia was defined as the time from obtaining the index blood culture to the first documented negative blood culture. Time to effective therapy was defined as the time from obtaining the culture to the time of administration of the first antibiotic with susceptibility in vitro. Duration of therapy was calculated as the difference between the first dose of effective antibiotic therapy and antibiotic discontinuation or discharge, whichever was sooner. Hospital LOS and infection-related LOS were calculated as the difference between admission and discharge date, and the difference between the date of culture obtainment and antibiotic discontinuation or discharge date, whichever was sooner, respectively. All-cause mortality was assessed from the day of culture obtainment. 
RESULTS

Demographic characteristics and potential risk factors
During the study period, 34 patients with SAGB were identified for inclusion. Demographic and baseline clinical characteristics are shown in Table 1 . Patients with SAGB had significant co-morbidities at baseline as evidenced by the median Charlson co-morbidity index of 4 (IQR 1-6), and approximately 30 % were immunosuppressed, including 12 (35 %) with gastrointestinal malignancies. Diabetes mellitus was the second most common co-morbidity identified, occurring in seven (21 %) patients. Almost half of the patients had received antibiotics in the previous 90 days and the most common source of bacteraemia was the gastrointestinal tract. When comparing patients who experienced a clinical cure versus those with a clinical failure, there were no statistically significant differences in demographic characteristics or clinical outcomes, except for a higher rate of mortality in those who experienced a clinical failure, as expected (Table S1 , available in the online Supplementary Material).
Microbiology and antimicrobial susceptibility
All but one patient had monomicrobial SAGB as identified by the Verigene BC-GP system. There were no discordant results encountered between the BC-GP and MicroScan Walkaway systems. Although the overall number of SAG isolates included in previous evaluations of the Verigence BC-GP system was low, the majority of reports have also observed 100 % accuracy for this group (Beal et al., 2013; Sullivan et al., 2013) . Species identification and characterization of haemolysis were able to be performed on 31 of the 34 SAG isolates. Susceptibility results from the full MICroSTREP plus panel were available for 16 isolates, 16 had only Etests performed and two failed to grow sufficiently for testing. The results by individual species of the SAG are shown in Table 2 . The vast majority of isolates were confirmed to be S. anginosus (68 %), followed by S. constellatus (16 %) and S. intermedius (16 %) and all displayed a-haemolysis with the exception of one bhaemolytic S. constellatus. No significant differences were observed in susceptibilities or clinical outcomes between the individual species of the SAG. Penicillin and clindamycin susceptibilities were comparable to previously documented SAG sensitivities at 91 and 88 % (Bourgault et al., 1979; Farber et al., 1983; Gó mez-Garcés et al., 1994) , while azithromycin susceptibilities were considerably lower at 63 %. Initially, one isolate tested non-susceptible to vancomycin Clinical outcomes in S. anginosus group bacteraemia at the local clinical microbiology laboratory but was later confirmed to be susceptible by a reference laboratory.
Antibiotic treatment
All 34 patients received systemic antimicrobial therapy. The mean time to initiation of effective therapy was 7+15 h and the median in-hospital duration of therapy was 8 (IQR 4-13) days. No patient received inappropriate empiric therapy. Thirty-one patients received vancomycin and/or a b-lactam as empiric antibiotic therapy, whereas the most common definitive therapy was a b-lactam/blactamase inhibitor combination (piperacillin/tazobactam or ampicillin/sulbactam). Five patients each received ertapenem, vancomycin or ceftriaxone, while three received penicillin G and one each received vancomycin, cefepime or moxifloxacin.
Aetiology and source control
The most common source of SAGB was the gastrointestinal tract (53 %), followed by bone and joint (21 %) or skin and soft tissue related (12 %). Two patients developed bacteraemia secondary to an oropharyngeal source and three were unknown. Eight patients had documented abscess formation secondary to SAG of which four were hepatic while the remainder were retroperitoneal, colonic, perirectal and supraclavicular. One patient had mitral and aortic valve endocarditis, and another was treated for suspected endocarditis due to the presence of septic pulmonary emboli on a computed tomography scan. Source removal was achieved successfully in 12 (35 %) patients, in a mean time of 2+2 days.
Clinical and microbiologic outcomes
The mean duration of SAGB was 2+1 days, while the median hospital LOS was 10 (IQR 5-17) days. LOS specifically related to SAGB was 9 (IQR 4-12) days. Ten (29 %) patients were admitted to the ICU during their hospitalization and stayed for 7 (IQR 4-11) days. Twenty-two (65 %) patients were evaluated by an ID physician within 3 (IQR 2-4) days of culture positivity. The majority (59 %) of patients achieved a clinical cure, while 85 % had documented clearance of blood cultures during the study period. The 30-day infection-related mortality rate was 12 % (four patients), and one patient was readmitted within 30 days due to a relapse of SAGB. Table S1 compares the characteristics and clinical outcomes of those patients who achieved a clinical cure versus those who did not. There were no significant differences between the groups other than attributable mortality, which was higher in the group that did not achieve a clinical cure, as expected.
DISCUSSION
The SAG has been identified as a formidable pathogen and one that requires aggressive surgical and medical management. Despite increased awareness and advanced identification techniques, clinicians continue to be challenged with the timely, effective treatment of invasive infections due to SAG, particularly SAGB. To the best of our knowledge, this is the largest cohort of SAGB reported to date, and considering that SAGB remains a relatively rare phenomenon, the 34 cases of bacteraemia during our 13-month study period represent a substantial increase compared with previous studies that observed up to 19 and 28 cases over a 7-and 3-year span, respectively (Bert et al., 1998; Jacobs et al., 2000; Salavert et al., 1996; Siegman-Igra et al., 2012; Weightman et al., 2004) . Prior to implementation of the BC-GP machine, the SAG was identified only as a-haemolytic, viridans group streptococci, and therefore many specific cases of SAGB went unidentified. The use of a rapid, microarray-based molecular identification technology allowed accurate identification of the SAG and differentiation from other viridans streptococci, while the inclusion of only patients with bacteraemia also eliminated much of the heterogeneity found in other studies evaluating the SAG or S. milleri group. Additionally, the majority of the isolates identified by the BC-GP system as SAG were in fact S. anginosus, improving the cohesiveness of our findings.
Similar to previous literature, the most common cause of SAGB in our cohort was the result of bloodstream invasion from the gastrointestinal tract in patients with altered gastrointestinal pathology, especially malignancies (Siegman-Igra et al., 2012) . Given the fact that the SAG are common gastrointestinal commensal organisms, it is not surprising that diseases affecting this area may be an important risk factor for SAGB. We also demonstrated the propensity for SAG to cause deep-seated abscesses, as has been reported previously (Claridge et al., 2001) , and we described two cases of proven or suspected endocarditis, an infrequent complication of SAG, while we observed surprisingly few oropharyngeal/dental sources of bacteraemia.
Testifying to the invasive nature of this pathogen, over onethird of our population required surgical source removal including for hepatic and colonic abscesses.
Mortality rates for infections due to SAG have ranged from 0 to 31.2 % (Belko et al., 2002; Molina et al., 1991) , but these studies often included non-bloodstream isolates and polymicrobial infections. The attributable mortality rate in our study may be improved due to the ability to rapidly identify SAG directly from positive blood cultures, therefore decreasing the time to effective therapy. The robust antimicrobial stewardship programme (ASP) in place at OSUWMC may also play a role in educating prescribers on the serious nature of SAG infections and increasing the awareness of appropriate management. Although there were no specific ASP interventions targeted at SAGB during the study period, the ASP receives an automated list of positive blood cultures for all inpatients at OSUWMC and provides recommendations at their discretion. All patients received appropriate empirical therapy quickly, and definitive treatment with a combination b-lactam/b-lactamase inhibitor seemed to be adequate, while resistance rates to macrolides and clindamycin were higher than previous reports (Bourgault et al., 1979; Farber et al., 1983; Gó mez-Garcés et al., 1994; Quinn et al., 1988) . As the majority of the SAGB in this cohort stemmed from the gastrointestinal tract, a combination b-lactam/b-lactamase inhibitor was often used as definitive therapy in order to cover for other potential common sitespecific pathogens, despite the fact that 33 (97 %) patients had monomicrobial SAGB.
Our study is not without limitations; it represented a small sample size and was a single-centre, non-randomized design. The number and timing of repeat blood cultures were not standardized and were left to the treating physician's discretion. We did not include a comparator group from which to identify confirmed risk factors and did not analyse the time to SAG identification pre-and post-BC-GP implementation.
This retrospective analysis of SAGB highlights the importance of the rapid and accurate identification of SAG along with proper aggressive source control and susceptibilityguided, timely antimicrobial therapy. As the SAG continues to attract increasing attention due to its pathogenicity and associated morbidity and mortality, it is imperative that clinical microbiology laboratories routinely differentiate these from other viridans streptococci and perform susceptibility testing. The improved speed and accuracy of the microarray technology allow better collaboration among the healthcare team including physicians, surgeons, pharmacists and microbiologists in order to improve patient outcomes with SAGB. Our study highlights the need for awareness and deliberate management of these infections and the continued vigilance in strategies to combat these challenging pathogens.
